Status:
COMPLETED
Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein Glomerulopathy
Lead Sponsor:
Nanjing University School of Medicine
Conditions:
Treatment
Eligibility:
All Genders
15-60 years
Phase:
NA
Brief Summary
The purpose of this study is to assess the efficacy and safety of immunoadsorption in the treatment of lipoprotein glomerulopathy.
Detailed Description
Lipoprotein glomerulopathy is characterized by nephritic syndrome glomerular protein thrombi and lipid abnormalities, particularly with an elevated level of plasma apoprotein E (apoE).There are no eff...
Eligibility Criteria
Inclusion
- A new diagnosis of lipoprotein glomerulopathy proved by histology and serology
- Age 15\~60 years, sex free
Exclusion
- Serum creatinine \> 500 umol/l
- Severe viral infection(HBV, HCV, CMV) within 3 months of first randomization or known HIV infection
- Congenital or acquired immunodeficiency
- Patients with severe infection or central nervous system symptoms
- Immediately life-threatening organ manifestations (e.g. lung haemorrhage or massive gastro-intestinal bleeding, heart failure due to pericarditis or myocarditis, liver dysfunction measured on at least 2 separate occasion)
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2003
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00302510
Start Date
January 1 2000
End Date
August 1 2003
Last Update
May 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine
Nanjing, Jiangsu, China, 210002